Medivir AB (FRA:MVR0) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience

GuruFocus News

Thu, February 19, 2026 at 4:01 AM GMT+9 3 min read

In this article:

MVIR.ST

+46.00%

MVR0.F

-26.93%

This article first appeared on GuruFocus.

Release Date: February 18, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Medivir AB (FRA:MVR0) has made significant progress in its pipeline, particularly with the initiation of clinical development for MIB 7-Eleven in osteogenesis imperfecta, a strategically important indication.

The company has received orphan drug designation from the FDA for MV 7-Eleven, which could expedite its development and approval process.

The collaboration with Doctorhong and the Korean Cancer Study Group is advancing well, with eight hospitals selected to participate in the study, indicating strong interest and support.

Medivir's partner, Vet Bolics, has shown promising results in a proof of concept study for MV 701 in periodontal disease in dogs, with 20% of subjects already recruited for the next study.

The company has a strong financial position, bolstered by a recent directed share issue, allowing continued development of key programs like MB 7-Eleven and Fostrox.

Negative Points

There are no approved systemic treatments for osteogenesis imperfecta, highlighting the challenges Medivir faces in developing a first-in-class treatment.

The failure of the phase 3 study for antisclerostin in OI indicates potential hurdles in developing effective treatments for this condition.

The company's operating loss for Q4 was higher than the previous year, partly due to a write-down of the Brina pump project.

The development and regulatory milestones for VBX 1,000 are described as small, indicating limited immediate financial returns from this program.

The timeline for the initiation of the phase 2 proof of concept study for MF 7-Eleven remains uncertain, with regulatory approvals still pending.

Q & A Highlights

Warning! GuruFocus has detected 5 Warning Signs with FRA:MVR0.

Is FRA:MVR0 fairly valued? Test your thesis with our free DCF calculator.

Q: Could you give us some more details about the path to market for MIV 7-Eleven? What additional studies are needed for approval? A: We see a two-step approach for MIV 7-Eleven in osteogenesis imperfecta. The first step is establishing clinical proof of concept with the current study, which will lead us into a pivotal phase of development. The next phase would involve a larger study, though not necessarily very large, to continue development. We are considering whether to combine adult and pediatric populations in one study or run them separately. CEO Jens Lindbergh

Q: Can you provide more details about the royalty agreement on VBX 1,000? A: We haven’t disclosed specific numbers, but the agreement with Vet Bolix focuses on a healthy share of royalties and potential partnership payments. The development and regulatory milestones are relatively minor, with the main focus on royalty revenue, which could align with our current market cap if successful. CEO Jens Lindbergh

Story Continues  

Q: What is the financial runway after the latest funding? A: With the recent directed share issue to Carl Bennett AB, we have a strong financial position. Our cash resources are sufficient to cover the planned phase 2 studies in liver cancer and osteogenesis imperfecta, with a cash runway extending into 2028 based on current plans. CFO Magnus Christensen

Q: Regarding the MIV 7-Eleven proof of concept study, where do you stand in terms of preparations, and how long will it take to finalize? A: We are currently preparing by assembling a scientific expert council to get external advice on patient population inclusion. The treatment time for patients is 12 months to reach the primary endpoint. The patients are already identified, which should facilitate quick recruitment. Chief Medical Officer Pia Baumann

Q: Is MIV 7-Eleven intended as a lifelong therapy for osteogenesis imperfecta patients? A: It depends on the severity of the disease and the patient’s age. For pediatric patients, treatment might be needed until they stop growing. For adults, it could be a sequenced treatment during periods when they need more support to maintain bone health. Chief Medical Officer Pia Baumann

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info